SpectraCure Financials
| SPEC Stock | SEK 1.92 0.02 1.03% |
SpectraCure |
Please note, the imprecision that can be found in SpectraCure's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SpectraCure AB. Check SpectraCure's Beneish M Score to see the likelihood of SpectraCure's management manipulating its earnings.
| Foreign Associate | USA |
| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0007158118 |
| Business Address | Gasverksgatan 1, Lund, |
| Sector | Healthcare |
| Industry | Medical Devices |
| Benchmark | Dow Jones Industrial |
| Website | www.spectracure.com |
| Phone | 46 46 16 20 70 |
| Currency | SEK - Swedish Kronor |
You should never invest in SpectraCure without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of SpectraCure Stock, because this is throwing your money away. Analyzing the key information contained in SpectraCure's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
SpectraCure Key Financial Ratios
SpectraCure's financial ratios allow both analysts and investors to convert raw data from SpectraCure's financial statements into concise, actionable information that can be used to evaluate the performance of SpectraCure over time and compare it to other companies across industries.| Return On Equity | -0.15 | |||
| Return On Asset | -0.0851 | |||
| Target Price | 8.26 | |||
| Number Of Employees | 15 | |||
| Beta | 0.98 |
SpectraCure Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SpectraCure's current stock value. Our valuation model uses many indicators to compare SpectraCure value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SpectraCure competition to find correlations between indicators driving SpectraCure's intrinsic value. More Info.SpectraCure AB is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SpectraCure's earnings, one of the primary drivers of an investment's value.SpectraCure AB Systematic Risk
SpectraCure's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SpectraCure volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on SpectraCure AB correlated with the market. If Beta is less than 0 SpectraCure generally moves in the opposite direction as compared to the market. If SpectraCure Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SpectraCure AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SpectraCure is generally in the same direction as the market. If Beta > 1 SpectraCure moves generally in the same direction as, but more than the movement of the benchmark.
SpectraCure March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SpectraCure help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SpectraCure AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of SpectraCure AB based on widely used predictive technical indicators. In general, we focus on analyzing SpectraCure Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SpectraCure's daily price indicators and compare them against related drivers.
| Downside Deviation | 9.81 | |||
| Information Ratio | 0.1064 | |||
| Maximum Drawdown | 121.32 | |||
| Value At Risk | (10.98) | |||
| Potential Upside | 15.81 |
Additional Tools for SpectraCure Stock Analysis
When running SpectraCure's price analysis, check to measure SpectraCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpectraCure is operating at the current time. Most of SpectraCure's value examination focuses on studying past and present price action to predict the probability of SpectraCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpectraCure's price. Additionally, you may evaluate how the addition of SpectraCure to your portfolios can decrease your overall portfolio volatility.